Lamotrigine treatment of aggression in female borderline patients, Part II: an 18-month follow-up
- PMID: 18308777
- DOI: 10.1177/0269881107084004
Lamotrigine treatment of aggression in female borderline patients, Part II: an 18-month follow-up
Abstract
Borderline patients often display pathological aggression. We previously tested lamotrigine, an anti-convulsant, in therapy for aggression in women with borderline personality disorder (BPD) (J Psychopharmacol 2005; 19: 287-291), and found significant changes on most scales of the State-Trait Anger Expression Inventory (STAXI) after eight weeks. To assess the longer-term efficacy of lamotrigine in therapy for aggression in women with BPD, this 18-month follow-up observation was carried out, in which patients (treated with lamotrigine: n = 18; former placebo group: n = 9) were tested every six months. According to the intent-to-treat principle, significant changes on all scales of the STAXI were observed in the lamotrigine-treated subjects. All subjects tolerated lamotrigine relatively well. Lamotrigine appears to be an effective and relatively safe agent in the longer-term treatment of aggression in women with BPD.
Similar articles
-
Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study.J Psychopharmacol. 2005 May;19(3):287-91. doi: 10.1177/0269881105051540. J Psychopharmacol. 2005. PMID: 15888514 Clinical Trial.
-
Treatment of aggression with topiramate in male borderline patients: a double-blind, placebo-controlled study.Biol Psychiatry. 2005 Mar 1;57(5):495-9. doi: 10.1016/j.biopsych.2004.11.044. Biol Psychiatry. 2005. PMID: 15737664 Clinical Trial.
-
Treatment of aggression with topiramate in male borderline patients, part II: 18-month follow-up.Eur Psychiatry. 2008 Mar;23(2):115-7. doi: 10.1016/j.eurpsy.2007.09.004. Epub 2007 Nov 19. Eur Psychiatry. 2008. PMID: 18024088 Clinical Trial.
-
Meta-analyses of mood stabilizers, antidepressants and antipsychotics in the treatment of borderline personality disorder: effectiveness for depression and anger symptoms.J Pers Disord. 2009 Apr;23(2):156-74. doi: 10.1521/pedi.2009.23.2.156. J Pers Disord. 2009. PMID: 19379093 Review.
-
Safety and tolerability of lamotrigine: results from 12 placebo-controlled clinical trials and clinical implications.Clin Neuropharmacol. 2011 Jan-Feb;34(1):39-47. doi: 10.1097/WNF.0b013e3182055c07. Clin Neuropharmacol. 2011. PMID: 21242744 Review.
Cited by
-
Pharmacological interventions for people with borderline personality disorder.Cochrane Database Syst Rev. 2022 Nov 14;11(11):CD012956. doi: 10.1002/14651858.CD012956.pub2. Cochrane Database Syst Rev. 2022. PMID: 36375174 Free PMC article. Review.
-
Safety profile of lamotrigine in overdose.Ther Adv Psychopharmacol. 2016 Dec;6(6):369-381. doi: 10.1177/2045125316656707. Epub 2016 Aug 8. Ther Adv Psychopharmacol. 2016. PMID: 28008350 Free PMC article. Review.
-
Lamotrigine in the treatment of unipolar depression with and without comorbidities: a literature review.Psychiatr Q. 2012 Sep;83(3):371-83. doi: 10.1007/s11126-012-9208-4. Psychiatr Q. 2012. PMID: 22322995 Review.
-
Current Clinical Psychopharmacology in Borderline Personality Disorder.Curr Neuropharmacol. 2021;19(10):1760-1779. doi: 10.2174/1570159X19666210610092958. Curr Neuropharmacol. 2021. PMID: 34151763 Free PMC article. Review.
-
HCN Channel Targets for Novel Antidepressant Treatment.Neurotherapeutics. 2017 Jul;14(3):698-715. doi: 10.1007/s13311-017-0538-7. Neurotherapeutics. 2017. PMID: 28560710 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
